Percentage of viable CLL B-cells 48 hours after nucleofection with control or Mcl-1 siRNA
| Patient . | Age/sex . | Clinical stage at dg. . | % CD38† . | % ZAP-70† . | VH gene (% hom.) . | FISH . | TTP* months . | Prior treatment . | % live with siControl . | % live with siMcl-1 . |
|---|---|---|---|---|---|---|---|---|---|---|
| G194 | 81 / m | A / 0 | 1 | 2 | Mut. V4–39 (91.2) | No abnormality | 36+ | no | 29% | 8% |
| G158 | 50 / m | A / 0 | 1 | 1 | Mut. V3–23 (92.7) | n.d. | 24+ | no | 15% | 7% |
| G159 | 73 / m | A / 0 | 3 | 1 | Mut. V1–46 (94.0) | No abnormality | 20+ | no | 66% | 33% |
| G53 | 67 / m | B / II | 1 | 8 | Mut. V3–53 (95.0) | No abnormality | 58+ | no | 40% | 14% |
| G160 | 64 / m | A / 0 | 20 | 57 | Unm V3–11 (100) | No abnormality | 42+ | no | 39% | 19% |
| G181 | 71 / m | B / II | 1 | 10 | Unm. V3–74 (100) | tris12 | 11 | no | 53% | 24% |
| G147 | 86 / f | A / 0 | 34 | 41 | Unm. V3–30 (100) | del11q22 | 16+ | no | 49% | 11% |
| G165 | 88 / f | A / I | 30 | 30 | Unm. V1–46 (100) | n.d. | 4+ | no | 56% | 29% |
| G130 | 73 / m | A / 0 | 1 | 3 | Mut. V4–34 (93.7) | No abnormality | 84+ | no | 61% | 22% |
| G109 | 70 / m | A / 0 | 3 | 5 | Mut. V3–53 (88.0) | del13q14 | 63+ | no | 35% | 15% |
| G212 | 65 / f | A / 0 | 1 | 1 | Unm. V3–30 (100) | No abnormality | 16+ | no | 45% | 27% |
| G28 | 58 / m | B / II | 3 | 5 | Mut. V3–74 (94.4) | del17p13 | 48 | yes | 14% | 5% |
| G61 | 71 / m | A / 0 | 2 | 8 | n.d. | No abnormality | 117+ | no | 42% | 10% |
| G213 | 70 / m | C / IV | 8 | 0 | Mut. V3–48 (95.6) | del17p13 | 48 | yes | 23% | 10% |
| G18 | 73 / m | B / II | 1 | 45 | Unm. V3–09 (100) | No abnormality | 66 | yes | 39% | 14% |
| G113 | 45 / f | A / 0 | 1 | 4 | Mut. V3–53 (90.7) | No abnormality | 24 | no | 60% | 23% |
| G169 | 58 / f | A / 0 | 1 | 3 | Mut. V3–72 (95.6) | del13q14 | 28+ | no | 55% | 23% |
| G4 | 72 / m | A / 0 | 6 | 78 | Unm. V3–73 (100) | del17p13 | 30 | yes | 80% | 51% |
| G29 | 65 / f | B / II | 1 | 13 | Mut. V4–34 (95.1) | No abnormality | 3 | yes | 38% | 12% |
| G34 | 68 / m | A / 0 | 4 | 29 | Unm. V1–69 (99.6) | del13q14 | 44 | yes | 32% | 15% |
| G42 | 50 / m | A / 0 | 1 | 13 | Mut. V3–23 (91.9) | No abnormality | 51+ | no | 39% | 24% |
| G45 | 56 / m | B / I | 30 | 35 | Unm. V3–11 (100) | del11q22 | 40 | yes | 40% | 21% |
| G63 | 79 / m | A / I | n.d. | 22 | Mut. V3–23 (90.8) | n.d. | 72 | yes | 61% | 33% |
| G164 | 68 / m | B / II | 73 | 41 | Mut. V3–49 (94.2) | del17p13; tris12 | 1 | yes | 36% | 15% |
| G175 | 65 / m | A / 0 | 1 | 31 | Unm V1–69 (100) | No abnormality | 6+ | no | 45% | 35% |
| G211 | 52 / m | A / 0 | 12 | 1 | n.d. | No abnormality | 38+ | no | 36% | 13% |
| G225 | 68 / m | B / II | 1 | 5 | n.d. | del13q14 | 6+ | no | 47% | 18% |
| G228 | 74 / f | B / I | 2 | 4 | n.d. | tris12 | 24+ | no | 63% | 37% |
| G229 | 59 / m | A / 0 | 43 | 7 | n.d. | n.d. | 96+ | no | 46% | 23% |
| G230 | 58 / f | A / 0 | 1 | 5 | Mut. 1–02 (93.4) | n.d. | 16+ | no | 40% | 29% |
| Patient . | Age/sex . | Clinical stage at dg. . | % CD38† . | % ZAP-70† . | VH gene (% hom.) . | FISH . | TTP* months . | Prior treatment . | % live with siControl . | % live with siMcl-1 . |
|---|---|---|---|---|---|---|---|---|---|---|
| G194 | 81 / m | A / 0 | 1 | 2 | Mut. V4–39 (91.2) | No abnormality | 36+ | no | 29% | 8% |
| G158 | 50 / m | A / 0 | 1 | 1 | Mut. V3–23 (92.7) | n.d. | 24+ | no | 15% | 7% |
| G159 | 73 / m | A / 0 | 3 | 1 | Mut. V1–46 (94.0) | No abnormality | 20+ | no | 66% | 33% |
| G53 | 67 / m | B / II | 1 | 8 | Mut. V3–53 (95.0) | No abnormality | 58+ | no | 40% | 14% |
| G160 | 64 / m | A / 0 | 20 | 57 | Unm V3–11 (100) | No abnormality | 42+ | no | 39% | 19% |
| G181 | 71 / m | B / II | 1 | 10 | Unm. V3–74 (100) | tris12 | 11 | no | 53% | 24% |
| G147 | 86 / f | A / 0 | 34 | 41 | Unm. V3–30 (100) | del11q22 | 16+ | no | 49% | 11% |
| G165 | 88 / f | A / I | 30 | 30 | Unm. V1–46 (100) | n.d. | 4+ | no | 56% | 29% |
| G130 | 73 / m | A / 0 | 1 | 3 | Mut. V4–34 (93.7) | No abnormality | 84+ | no | 61% | 22% |
| G109 | 70 / m | A / 0 | 3 | 5 | Mut. V3–53 (88.0) | del13q14 | 63+ | no | 35% | 15% |
| G212 | 65 / f | A / 0 | 1 | 1 | Unm. V3–30 (100) | No abnormality | 16+ | no | 45% | 27% |
| G28 | 58 / m | B / II | 3 | 5 | Mut. V3–74 (94.4) | del17p13 | 48 | yes | 14% | 5% |
| G61 | 71 / m | A / 0 | 2 | 8 | n.d. | No abnormality | 117+ | no | 42% | 10% |
| G213 | 70 / m | C / IV | 8 | 0 | Mut. V3–48 (95.6) | del17p13 | 48 | yes | 23% | 10% |
| G18 | 73 / m | B / II | 1 | 45 | Unm. V3–09 (100) | No abnormality | 66 | yes | 39% | 14% |
| G113 | 45 / f | A / 0 | 1 | 4 | Mut. V3–53 (90.7) | No abnormality | 24 | no | 60% | 23% |
| G169 | 58 / f | A / 0 | 1 | 3 | Mut. V3–72 (95.6) | del13q14 | 28+ | no | 55% | 23% |
| G4 | 72 / m | A / 0 | 6 | 78 | Unm. V3–73 (100) | del17p13 | 30 | yes | 80% | 51% |
| G29 | 65 / f | B / II | 1 | 13 | Mut. V4–34 (95.1) | No abnormality | 3 | yes | 38% | 12% |
| G34 | 68 / m | A / 0 | 4 | 29 | Unm. V1–69 (99.6) | del13q14 | 44 | yes | 32% | 15% |
| G42 | 50 / m | A / 0 | 1 | 13 | Mut. V3–23 (91.9) | No abnormality | 51+ | no | 39% | 24% |
| G45 | 56 / m | B / I | 30 | 35 | Unm. V3–11 (100) | del11q22 | 40 | yes | 40% | 21% |
| G63 | 79 / m | A / I | n.d. | 22 | Mut. V3–23 (90.8) | n.d. | 72 | yes | 61% | 33% |
| G164 | 68 / m | B / II | 73 | 41 | Mut. V3–49 (94.2) | del17p13; tris12 | 1 | yes | 36% | 15% |
| G175 | 65 / m | A / 0 | 1 | 31 | Unm V1–69 (100) | No abnormality | 6+ | no | 45% | 35% |
| G211 | 52 / m | A / 0 | 12 | 1 | n.d. | No abnormality | 38+ | no | 36% | 13% |
| G225 | 68 / m | B / II | 1 | 5 | n.d. | del13q14 | 6+ | no | 47% | 18% |
| G228 | 74 / f | B / I | 2 | 4 | n.d. | tris12 | 24+ | no | 63% | 37% |
| G229 | 59 / m | A / 0 | 43 | 7 | n.d. | n.d. | 96+ | no | 46% | 23% |
| G230 | 58 / f | A / 0 | 1 | 5 | Mut. 1–02 (93.4) | n.d. | 16+ | no | 40% | 29% |
TTP indicates time to progression; n.d., not determined; +, cases that have not progressed during follow-up; and dg, diagnosis.